CardiacWire

APRIL 10, 2024

Interventional Innovations – Interventional cardiology was the clear winner at ACC24, with numerous trials supporting an expanded role for interventional procedures across a wider range of conditions than we ever could have imagined five years ago.

Innovation 59

Innovation Technology Interventional Cardiology Medicare 59

GEMMS

APRIL 8, 2024

With the recent changes to MIPS reporting requirements, healthcare providers seek innovative solutions to streamline their reporting processes while maximizing incentives and improving patient care. What is MIPS?

Medicare 52

Medicare Innovation Medicaid Patient Care 52

Wellnest

JUNE 19, 2023

The development has urged us to integrate the latest Artificial Intelligence with the healthcare system, including Cardiac Medicare. By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patient care. What is Artificial Intelligence? For instance: 1.

Technology 52

Technology Cardiac Arrest Innovation Coronary Artery Disease 52

DAIC

JANUARY 3, 2024

3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. With more than 500 peer-reviewed publications, the HeartFlow FFR CT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes.

Coronary Artery Disease 59

Coronary Artery Disease Chest Pain Plaque Technology 59

DAIC

MARCH 5, 2024

He has 15 years’ experience with e-government development, but has found his heart is in digital health and innovation. These sessions will be offered throughout the conference week, according to HIMSS24 program planners. These sessions will be offered throughout the conference week, according to HIMSS24 program planners.

CMS 52

CMS COVID-19 Medicare Education 52

GEMMS

MARCH 7, 2024

In late 2023, CMS released the 2024 Medicare Physician Fee Schedule (MPFS) Final Rule, ushering in key policy changes for the Quality Payment Program (QPP). Benchmarks for the 2023 performance period for eCQMs, MIPS CQMs, QCDR measures, and Medicare Part B claims are based on actual performance data submitted for the 2021 performance period.

Medicare 52

Medicare CMS Document Technology 52

DAIC

MARCH 28, 2025

v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.

Technology 59

Technology Coronary Artery Disease Atrial Fibrillation Medicare 59

DAIC

DECEMBER 5, 2024

The company’s advanced non-invasive computed tomography (CT) imaging technology enables comprehensive phenotyping of coronary artery disease, grounded in scientific research based on millions of medical images. We’re proud to be a part of Cleerly’s journey. This is what good software can do in the world!"

Coronary Artery Disease 52

Coronary Artery Disease Medicare Plaque Technology 52

DAIC

MARCH 31, 2025

tim.hodson Mon, 03/31/2025 - 15:02 March 31, 2025 iRhythm Technologies, Inc. These findings challenge the long-held assumption that frequent symptoms justify short-duration monitoring, said Mintu Turakhia, MD, iRhythm Chief Medical and Scientific Officer and EVP of Product Innovation. iRhythm Technologies, 2025. Am Heart J.

Arrhythmia 52

Arrhythmia Atrial Fibrillation Tachycardia Heart Failure 52

DAIC

MARCH 7, 2024

Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and discussed at the Radiological Society of North America109th Scientific Assembly and Annual Meeting (RSNA23). As a whole, the computed tomography market size in the US in 2024 is estimated to be $2.38 Halpern, MD, and Vijay M.

Technology 111

Technology Document Cardiovascular Imaging Cancer 111

DAIC

MAY 8, 2024

2-4 HeartFlow’s non-invasive FFR CT technology has emerged as a leading frontline strategy for accurately diagnosing hemodynamically significant coronary lesions in patients suspected of having CAD. Longitudinal assessment of safety of FEMOROPOPLITEAL endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries.”

Coronary Artery Disease 111

Coronary Artery Disease Chest Pain Ischemia Myocardial Infarction 111

DAIC

JANUARY 27, 2025

13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

CMS 52

CMS Blood Pressure Medicare Hypertension 52